Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
(PubMed) Wang ZJ, Hu WK, Liu YY, et al
The Research Evidence Base Understanding the current state of BPC-157 research helps set appropriate expectations and supports informed decision-making
Serotonin Syndrome Counteraction A 2005 study in the European Journal of Pharmacology (PMID: 15840402) induced severe serotonin syndrome using pargyline (MAO inhibitor) plus L-tryptophan (serotonin precursor), producing forepaw treading, hindlimb abduction, wet dog shake, and hyperthermia mediated primarily through 5-HT2A receptors
Researchers reported that growth hormone may increase lean body mass, while AOD 9604 did not appear to show the same trend
The FDA has scheduled a Pharmacy Compounding Advisory Committee meeting for July 23, 2026 to review BPC-157 for the 503A Bulks List
